Role of Corticosteroids in Managing Severe Pneumonia

Mechanism and Benefits

Corticosteroids reduce overwhelming inflammation by decreasing cytokine release and help with inadequate adrenal response in critically ill patients 2
The American Thoracic Society recommends that corticosteroids reduce the risk of developing acute respiratory distress syndrome (ARDS) in severe community-acquired pneumonia (CAP) patients 1
Corticosteroids decrease the duration of mechanical ventilation by approximately 7 days in severe CAP patients 1
The use of corticosteroids can reduce time to clinical stability in severe CAP patients, according to the Infectious Diseases Society of America 2, 4

Meta-analyses of randomized trials in severe CAP have found significant mortality benefits with corticosteroid treatment, with an odds ratio of 0.39 (95% CI 0.17–0.90) 4
The Infectious Diseases Society of America found that adjunctive corticosteroids were associated with reduced all-cause mortality in severe CAP patients 4

For severe CAP, the Society of Critical Care Medicine recommends methylprednisolone 0.5 mg/kg every 12 hours for 5-7 days, particularly in patients with high C-reactive protein (>150 mg/L) 2
Alternatively, hydrocortisone at doses <400 mg daily for 5-7 days can be used, as suggested by the American College of Chest Physicians 3
Early initiation of corticosteroids (<72 hours) shows better response than late initiation (≥7 days) in severe CAP patients, according to the European Respiratory Society 1

The best candidates for corticosteroid therapy include patients with severe CAP and high inflammatory markers (e.g., CRP >150 mg/L), as recommended by the American Thoracic Society 2
Patients with early moderate to severe ARDS (PaO₂/FiO₂ <200 and within 14 days of onset) may benefit from corticosteroids, according to the Society of Critical Care Medicine 1
Patients with septic shock refractory to fluid resuscitation requiring vasopressors may also benefit from corticosteroids, as suggested by the Infectious Diseases Society of America 2, 4

The IDSA/ATS 2019 guideline gives a conditional recommendation against routine use of corticosteroids in all CAP patients, but acknowledges potential benefit in severe cases, as stated by the American Thoracic Society 2, 5
Corticosteroids are not recommended for mild cases of CAP, according to the American College of Physicians 5, 6
Patients with severe influenza pneumonia should not receive corticosteroids, as they may increase mortality, as warned by the Centers for Disease Control and Prevention 2, 5

Potential adverse effects of corticosteroids include hyperglycemia, which is the most common adverse effect, especially within 36 hours following initial bolus, as reported by the European Respiratory Society 1

For COVID-19 pneumonia, dexamethasone 6 mg daily for up to 10 days has shown mortality benefit in patients requiring oxygen or mechanical ventilation, as recommended by the World Health Organization 6, 7